AHA blog: PhRMA report misleads on drug costs
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs for Americans, writes AHA Executive Vice President Tom Nickels.
Related News Articles
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…